Immunome (IMNM) EBIT Margin (2023 - 2025)
Historic EBIT Margin for Immunome (IMNM) over the last 3 years, with Q2 2025 value amounting to 1157.61%.
- Immunome's EBIT Margin rose 5348200.0% to 1157.61% in Q2 2025 from the same period last year, while for Sep 2025 it was 2419.9%, marking a year-over-year increase of 7145000.0%. This contributed to the annual value of 3382.37% for FY2024, which is 26010200.0% down from last year.
- Immunome's EBIT Margin amounted to 1157.61% in Q2 2025, which was up 5348200.0% from 1525.5% recorded in Q1 2025.
- Immunome's 5-year EBIT Margin high stood at 129.96% for Q3 2023, and its period low was 12857.05% during Q1 2024.
- In the last 3 years, Immunome's EBIT Margin had a median value of 1608.96% in 2025 and averaged 2492.75%.
- In the last 5 years, Immunome's EBIT Margin tumbled by -126679200bps in 2024 and then skyrocketed by 113315500bps in 2025.
- Quarter analysis of 3 years shows Immunome's EBIT Margin stood at 2473.94% in 2023, then decreased by -22bps to 3030.31% in 2024, then skyrocketed by 62bps to 1157.61% in 2025.
- Its EBIT Margin was 1157.61% in Q2 2025, compared to 1525.5% in Q1 2025 and 3030.31% in Q4 2024.